SX-682
Oncology (Immuno-oncology)
Clinical DevelopmentActive
Key Facts
Indication
Oncology (Immuno-oncology)
Phase
Clinical Development
Status
Active
Company
About Syntrix Pharmaceuticals
Syntrix Pharmaceuticals is a private, clinical-stage biotech company leveraging a technology-agnostic, needs-driven research approach to develop novel therapeutics. Its pipeline features advanced clinical candidates in immuno-oncology (SX-682) and pain (desmetramadol), supported by a lean management team and a prestigious network of scientific advisors from top cancer centers. The company's strategy combines internal medicinal chemistry discovery with external collaboration and potential strategic acquisitions to build a robust portfolio targeting cancer and inflammatory diseases.
View full company profileTherapeutic Areas
Other Oncology (Immuno-oncology) Drugs
| Drug | Company | Phase |
|---|---|---|
| HTL0039732 | Nxera Pharma | Phase 1 |